Long-term treatment with proton pump inhibitor is associated with undesired weight gain.

Third Department of Internal Medicine, University of Occupational and Environmental Health, Japan, School of Medicine, Kitakyushu, Japan.
World Journal of Gastroenterology (Impact Factor: 2.43). 10/2009; 15(38):4794-8.
Source: PubMed

ABSTRACT To examine the effects of long-term proton pump inhibitor (PPI) therapy on body weight (BW) and body mass index (BMI) in patients with gastroesophageal reflux disease (GERD).
The subjects were 52 patients with GERD and 58 sex- and age-matched healthy controls. GERD patients were treated with PPI for a mean of 2.2 years (range, 0.8-5.7 years), and also advised on lifestyle modifications (e.g. selective diet, weight management). BW, BMI and other parameters were measured at baseline and end of study.
Twenty-four GERD patients were treated daily with 10 mg omeprazole, 12 with 20 mg omeprazole, 8 with 10 mg rabeprazole, 5 with 15 mg lansoprazole, and 3 patients with 30 mg lansoprazole. At baseline, there were no differences in BW and BMI between reflux patients and controls. Patients with GERD showed increases in BW (baseline: 56.4 +/- 10.4 kg, end: 58.6 +/- 10.8 kg, mean +/- SD, P < 0.0001) and BMI (baseline: 23.1 +/- 3.1 kg/m(2), end: 24.0 +/- 3.1 kg/m(2), P < 0.001), but no such changes were noted in the control group. Mean BW increased by 3.5 kg (6.2% of baseline) in 37 (71%) reflux patients but decreased in only 6 (12%) patients during treatment.
Long-term PPI treatment was associated with BW gain in patients with GERD. Reflux patients receiving PPI should be encouraged to manage BW through lifestyle modifications.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Gastroesophageal reflux can cause inflammation, metaplasia, dysplasia and cancer of the esophagus. Despite the increased use of Proton Pump Inhibitors (PPIs) to treat reflux, the incidence of esophageal adenocarcinoma has increased rapidly in Europe and the United States in the last 25 years. The reasons for this increase remain unclear. In this study we aimed to determine whether the microbiota of the gastric refluxate and esophageal biopsies differs between patients with heartburn and normal appearing esophageal mucosa vs. patients with abnormal esophageal mucosa [esophagitis or Barrett's esophagus (BE)] and to elucidate the effect of PPIs on the bacterial communities using 16S rRNA gene pyrosequencing. Significant differences in the composition of gastric fluid bacteria were found between patients with heartburn and normal esophageal tissue vs. patients with esophagitis or BE, but in the esophagus-associated microbiota differences were relatively modest. Notably, increased levels of Enterobacteriaceae were observed in the gastric fluid of esophagitis and BE patients. In addition, treatment with PPIs had dramatic effects on microbial communities both in the gastric fluids and the esophageal tissue. In conclusion, gastric fluid microbiota is modified in patients with esophagitis and Barrett's esophagus compared to heartburn patients with normal biopsies. Furthermore, PPI treatment markedly alters gastric and esophageal microbial populations. Determining whether the changes in bacterial composition caused by PPIs are beneficial or harmful will require further investigation.
    Environmental Microbiology 09/2013; 16(9). DOI:10.1111/1462-2920.12285 · 6.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: With obesity having grown to epidemic proportions, nearly half of women of reproductive age are overweight and obese and this is a major public health problem. Due to unfavourable ovarian stimulation protocols, higher gonadotropin consumption and poor results most insurance companies are reluctant to sponsor treatment for such patients .Since diet and exercise are inadequate treatments and bariatric surgery maybe too extreme, treatment in the model of other chronic diseases by combination therapies has prompted the development of novel combination therapies like Qysmia (topiramate/phentermine)/Contrave (Bupropion SR/Naltrexone SR) which simultaneously target multiple physiological pathways that regulate energy homeostasis to overwhelm endogenous compensatory mechanisms as opposed touse of monotherapies to maintain weight loss. The only concern is the slight risk of teratogenicity with topiramate hence it is better to use contraception while using topiramate/bupropionSR/naltrexoneSR. In obese diabetics the GLP-1 receptor agonists like exenatide/liraglutide remain the drugs of choice incombination with insulin, while combination of lixisenatide and insulinglargine are in the pipeline for the future. Keywords: Obesity, infertility, Qnexia, topiramate, phentermine, contrave, bupropion SR, Naltrexone SR, Combination drugs.
    01/2013; 3(3):174-190. DOI:10.6000/1927-5961.2013.03.03.2
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Laparoscopic Roux-en-Y gastric bypass (LRYGB) achieves sustainable weight loss possibly by altering the gut microbiota. The effect of a proton pump inhibitor (PPI) on weight loss and the gut microbiota has not been explored. PPI use and the gut microbiota were assessed before and 6 months after LRYGB in eight patients. Bacterial profiles were generated by 16S ribosomal RNA (rRNA) gene sequencing. Prior to LRYGB, PPI users had a higher percent relative abundance (PRA) of Firmicutes compared to nonusers. PPI users at 6 months post-LRYGB had a higher PRA of Firmicutes [48.6 versus 35.6 %, p = nonsignificant (NS)] and a trend toward significantly lower percent excess weight loss (49.3 versus 61.4 %, p = 0.067) compared to nonusers. PPI use post-LRYGB may impair weight loss by modifying gut microbiota.
    Obesity Surgery 05/2014; 24(9). DOI:10.1007/s11695-014-1275-1 · 3.74 Impact Factor